Fate Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	40.62	36.06	41.87	61.33	133.58	167.35
Short-Term Investments	174.8	243.01	273.31	374.89	482.33	315.57
Cash & Short-Term Investments	215.42	279.07	315.18	436.23	615.91	482.92
Cash Growth	-27.45%	-11.46%	-27.75%	-29.17%	27.54%	118.09%
Accounts Receivable	0.68	3.54	1.83	38.48	8.68	5.52
Other Receivables	1.4	2.1	0.9	0.8	1.1	1.5
Receivables	2.08	5.64	2.73	39.28	9.78	7.02
Prepaid Expenses	3.75	7.2	13.64	26.57	7.73	4.39
Total Current Assets	221.25	291.91	331.54	502.07	633.41	494.32
Property, Plant & Equipment	101.89	110.89	158.51	176.09	162.25	99.39
Long-Term Investments	10.31	27.66	0.98	4.94	100.66	-
Long-Term Deferred Charges	-	-	-	7.2	9.87	13.51
Other Long-Term Assets	10.23	10.24	15.19	15.26	15.26	15.24
Total Assets	343.67	440.69	506.22	705.56	921.46	622.46
Accounts Payable	3.5	9.37	4.72	8.27	8.61	6.28
Accrued Expenses	17.57	21.35	27.51	53.93	42.41	15.56
Current Portion of Leases	4.75	7.42	6.18	5.63	5.58	3.36
Current Unearned Revenue	0.01	0.39	0.69	42.23	21.48	21.14
Other Current Liabilities	2.28	-	-	4	3.2	39.22
Total Current Liabilities	28.11	38.52	39.09	114.05	81.28	85.56
Long-Term Leases	74.49	77.85	97.36	103.71	109.24	93.94
Long-Term Unearned Revenue	-	-	-	-	27.12	46.02
Other Long-Term Liabilities	7	5.6	1.35	3.86	24.97	12.48
Total Liabilities	109.61	121.97	137.8	221.62	242.62	238.01
Common Stock	0.12	0.11	0.1	0.1	0.1	0.09
Additional Paid-In Capital	1,736	1,716	1,580	1,536	1,449	941.22
Retained Earnings	-1,502	-1,398	-1,212	-1,051	-769.08	-556.93
Comprehensive Income & Other	0.15	0.27	0.02	-1.85	-0.76	0.07
Total Common Equity	234.06	318.72	368.41	483.94	678.84	384.44
Shareholders' Equity	234.07	318.73	368.42	483.94	678.84	384.45
Total Liabilities & Equity	343.67	440.69	506.22	705.56	921.46	622.46
Total Debt	79.25	85.27	103.54	109.34	114.82	97.3
Net Cash (Debt)	136.18	193.8	211.64	326.89	501.09	385.62
Net Cash Growth	-31.20%	-8.43%	-35.26%	-34.77%	29.95%	98.26%
Net Cash Per Share	1.15	1.70	2.15	3.38	5.29	4.68
Filing Date Shares Outstanding	115.35	114.6	99.24	98.16	96.43	93.78
Total Common Shares Outstanding	115.34	113.93	98.63	97.29	95.73	87.72
Working Capital	193.14	253.39	292.45	388.02	552.13	408.76
Book Value Per Share	2.03	2.80	3.74	4.97	7.09	4.38
Tangible Book Value	234.06	318.72	368.41	483.94	678.84	384.44
Tangible Book Value Per Share	2.03	2.80	3.74	4.97	7.09	4.38
Machinery	-	38.85	83.29	81.5	53.63	22.25
Construction In Progress	-	-	-	-	-	18.19
Leasehold Improvements	-	59.49	59.04	56.78	52.95	2.7

Source: S&P Global Market Intelligence. Standard template. Financial Sources.